|
The Dual-Glo™ Luciferase Assay System(a,b,c,d) provides
high z-factors and reliable results for cell-based highthroughput
screening applications. The system enables the fastest and simplest,
independent measurement of stable luminescence from two reporter
genes in a single sample. In the Dual-Glo™ Luciferase Assay, the
activity of your primary reporter is correlated with the effect
of specific stimuli and the activity of the co-transfected control
reporter provides an internal control to normalize results. Not
only do you get reduced sample variability (one of the primary sources
of error in cell based screening), you now have a simple, robust
and elegant solution for discriminating between specific down regulation
and cytotoxicity in the same assay!
|
Advantages of The Dual-Glo™ Luciferase Assay System
|
| |
|
|
|
Increased Precision and Accuracy:
Normalize your primary reporter results with an internal
control. Co-reporter minimizes effects of cell number, cell
health, transfection efficiency and non-specific cellular
responses.
Homogeneous Format:
Perform fewer steps. Cells may be assayed directly in growth
medium for both reporters. No centrifugation required.
Stable Signal:
Obtain flexibility for either batch or continuous processing
of 96, 384 & 1536 well plates. Each luminescent signal may
be measured for up to 2 hours after reagent addition.
|
|
Convenience:
Screen efficiently with this simple, two-step assay that
is ideal for your luminometer. Injectors not required.
Wide Range:
Analyze high and low reporter activity without sample dilution.
Linear over at least 6 logs of enzyme concentration for
each reporter. |
| |
|
|
|
With the Dual-Glo™ Assay, you have a powerful and reliable method to deconvolute
your data by enabling you to discriminate between specific
and non-specific cellular responses. Single reporter, uncorrected
data cannot distinguish between specific down regulation
and cytotoxicity, as both responses exhibit a similar decrease
in luminescence. In the Dual-Glo ™ Assay, however, the use
of dual reporters can discriminate these responses through
normalization. |
| |
|
|
|
| |
|
|
|
Figure 1. Single Reporter, uncorrected
data cannot distinguish specific down regulation from a
cytotoxic response: Transiently transfected CHO cells
expressing Renilla luciferase under control of the
Tet-Off promoter and firefly luciferase under the control
of the CMV promoter (luc+ in pCI plasmid from Promega) were
exposed to varying concentrations of either Doxycycline
(a specific inhibitor that down regulates expression of
the Tet-Off promoter) or G418 (a general inhibitor which
is cytotoxic to cells). All data was generated using the
Dual-Glo™ Luciferase Assay System.
Panel A: Luminescence from the uncorrected experimental
reporter, Renilla luciferase, is shown compared to
the concentration of the inhibitor Doxycylcine.
Panel B: Luminescence from the uncorrected experimental
reporter, Renilla luciferase, is shown compared to
the concentration of the general inhibitor G418. The data
illustrates that single reporter results cannot distinguish
between cytotoxicity and specific down regulation. Non-normalized
Reporter CV= 22%.
|
| |
|
|
|
| |
|
|
|
Figure 2. Dual Reporter, corrected data can isolate specific
down regulation from a cytotoxic response: Renilla
Luciferase luminescence is normalized to the luminescence
of the co-expressed firefly luciferase. This relative effect
is then correlated to the maximal response to generate a
Relative Response Ratio (RRR= [ratio of normalized experimental
sample - ratio of untreated sample]/[ratio at the maximum
effect (200 µg/ml doxycycline) - ratio of untreated sample].
Panel C: The Relative Response Ratio is shown compared
to the concentration of the specific inhibitor, Doxycycline.
Panel D: The Relative Response Ratio is shown for
the general inhbitor, G418. The data demonstrates that by
normalizing the Renilla luciferase expression to
the firefly luciferase expression to generate a Relative
Response Ratio results in the differentiation of a specific
response from a non-specific response. Relative Response
Ratio CV = 13%. For all data points, n=12 wells in a 96-well
plate, integration time=0.5 seconds per well. Tet-Off plasmids
pUHD15-1 and pUHD10-3 provided by B Callus (Dana-Farber
Cancer Institute, 44 Binney Street, Boston, MA 02115).
|
| |
|
|
|
| |
|
|
|
Technical Resources for all Luminescence products
|
| |
|
|
|
(a) Products may be covered by issued or pending patents.
(b) U.S. Pat. No. 5,744,320, Australian Pat. No. 721172
and other patents pending.
(c ) U.S. Pat. Nos. 5,283,179, 5,641,641, 5,650,289, 5,814,471,
Australian Pat. No. 649289 and other patents pending.
(d) Certain applications of this product may require licenses
from others.
Dual-Glo, Bright-Glo and DLReady are trademarks of Promega
Corp. Dual-Luciferase, Steady-Glo and Stop & Glo are trademarks
of Promega Corporation and are registered with the U.S.
Patent and Trademark Office. |
|
|